1 / 63

Therapeutics in Hepatobiliary

Therapeutics in Hepatobiliary. Disease. Narelle Brown. Animal Referral Hospital. 30/04/10. Section 1. Antibiotic Therapy. When To Consider Antibiotic Therapy?. Increased risk of infection EHBDO Chronic liver Dz with portal hypertension Compromised hepatic perfusion /bile flow

lethia
Download Presentation

Therapeutics in Hepatobiliary

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Therapeutics in Hepatobiliary Disease Narelle Brown Animal Referral Hospital 30/04/10

  2. Section 1 Antibiotic Therapy

  3. When To Consider Antibiotic Therapy? • Increased risk of infection • EHBDO • Chronic liver Dz with portal hypertension • Compromised hepatic perfusion /bile flow • Enteric Bacterial Translocation • Bowel Dz • Bacterial dysbiosis • Splanchnic Hypoperfusion

  4. Hepatobiliary Infections • Considerations: • primary Vs secondary infections • “innocent Bystander” • effects on antibiotic metabolism (dose and dosing frequency) • bacteria found in bile/liver/GB :enteric origin • E Coli, Clostridium, Enterococcus sp • anaerobic and gm neg bacteria • ideally based on culture and sensitivity

  5. Samples for culture • Cholecystocentesis • Not advised if EHBDO or US changes necrotizing cholecystitis • Transhepatic approach • Limits bile extravasation • Drain as much of the bile as possible • Submit sample in culture bottle • US guidance (22G spinal needle) • Recheck US 24-48hrs later

  6. Samples for culture:Liver Abscess • Ultrasound guided • May be only therapy required if complete drainage • Generally better to surgically explore once stable as often associated with necrotic center (neoplasia) or migrating FB

  7. Samples for Culture:Liver Biopsy • surgically • Tru-Cut (ultrasound guided) , • laproscopy • Sample liver tissue for culture (into sterile , sealed container) • Assess patients ability to clot BEFORE you do the biopsy

  8. General guidelines • In the absence of C+S: • Cover aerobic and anaerobic enteric orgs • B lactamase resistance penicillin OR metronidazole OR clindamycin • PLUS • Aminoglycoside or fluorinated quinolone • Start treatment BEFORE sx if EHBDO or known infection

  9. Antibiotics • Antibiotics that achieve therapeutic concentrations in liver and bile, renal excretion: • Amoxicillin 11-20mg/kg PO,IV,IM BID • Cephalexin 15mg/kg PO, SQ, IV BID-TID • Ticarcillin 50mg/kg IV TID • Enrofloxacin 2.5-5mg/kg PO, SQ BID

  10. Metronidazole • Dose: 7.5mg/kg PO , IV, rectal BID-TID • High bioavailability • Wide tissue distribution (bone/bile/CSF,brain/prostate/ascites) • Note “Liver “dose • Important action against many urease producers (decrease ammonia production) • Immunosuppressive activity • Overdose: cerebellar/central vestibular signs/seizures

  11. Neomycin • Can be used alone or is synergistic with lactulose in effects on gut flora (decrease ammonia production) • Not systemically absorbed • Beware if concurrent IBD as may be absorbed • May improve portal hypertension • 22mg/kg Po BID-TID

  12. Chloramphenicol • ???? • If you have to use it use a low dose : • 11mg/kg PO, SQ, IV BID • Inactivates mixed function oxidases in liver>>>>> adverse drug reactions • Anorexia / Erythroid hypoplasia • Bone marrow injury in humans

  13. Antibiotics to Avoid • Tetracyclines • Lincomycin • Erythromycin • Trimethoprim-Sulphonamides • Either inactivated by liver, require hepatic metabolism or can injure liver

  14. REMEMBER • Hepatobilary disease can influence the clearance and volume of distribution of drugs • See table in Greenes Infectious diseases

  15. Section 2 Detoxification/Removal Intestinal Toxins

  16. Lactulose • Decrease intestinal ammonia production • Decrease ammonia absorption • Antiendotoxin effect • Indicated for treatment hepatic encephalopathy • Works synergistically with neomycin • 0.25-1.0 ml PO per 5kg • Adjust dose to achieve 2-3 soft stools /day

  17. Enemas • Perform a “mechanical enema “ first to flush faecal contents from colon • Retention enemas for a prolonged effect • Lactulose: 5-15ml diluted 1:3 with water: • retain 20-30 mins . If faecal pH >6 repeat • Activated charcoal • Vinegar :dilute 1:10 with water BID-TID • Betadine :dilute 1:10 in water :flush out • after 10-15 mins :BID-TID

  18. Section 3 Gastric Protectants

  19. Gastric protectants • Animals with chronic major bile duct obstruction at an increased risk gastroduodenal ulceration/perforation • H2 Receptor antagonists • Cimetidine (??) • Suppression cytochrome P450 oxidases • Most cases increases pharmacologic effects or toxicity of concomitant drugs • 5mg/kg IM, IV, PO BID-TID • Famotidine • 20-30x more potent than cimetidine • 0.4-0.7mg/kg PO, IV (SID if PO , BID if IV)

  20. Proton Pump Inhibitors • Omeprazole • 5-10 fold more potent than cimetidine • Inhibits p450 cytochrome oxidases similar to cimetidine • 0.7-2mg/kg PO SID (dogs) • Limited experience with this drug in cats

  21. Gastric Cytoprotection • Sucralfate • Direct action on mucosal prostoglandin E production • Binds to surface mucosal ulcers/protective barrier • Inhibits pepsin activity • Does NOT require an acid environment to be effective (no need to stagger dose with antacid) ? • Will interfere with absorption of drugs orally administered • It inactivates fluoroquinolones • May promote constipation

  22. Sulcralfate • DOSE: • Large dogs: 1g, PO BID-QID • Medium dogs: 0.5gm PO BID-QID • Small Dogs/Cats: 0.12-0.25g PO BID-QID • May cause oesophageal impaction so best mixed with water and given via syringe

  23. Section 4 Antiemetic Therapy

  24. Metoclopramide (Maxalon) • Impaired hepatic function decreases plasma clearance by 25% • Normal dose: 0.2-0.4mg/kg PO TID-QID • 1-2mg/kg/24hours CRI • 25% reduced dose: 0.13-0.3mg/kg PO TID -QID • 0.75-1.5mg/kg/24hours CRI IV

  25. Ondansetron (Zofran) • Good anti-emetic effect in patients with poor responsive to maxalon • $$$$ • Dose: • 0.1-1.0mg/kg PO q12hours(use low end dose range with liver dz as eliminated by hepatic metabolism) • Cats: 0.1-0.5mg/kg PO BID-SID

  26. Maropitant (Cerenia) • NK1 antagonist • Good anti-emetic • Dose:1mg/kg s/c SID or 2mg/kg PO SID

  27. Section5 Immunosuppressive/Immunomodulatory Therapy

  28. Immunosuppressant/Immunomodulatory Therapy • Glucocorticoids • Azathioprine • Ursodeoxycholic Acid

  29. Indications Antifibrotic (weak) Non septic active inflammation Immunologic Injury Promote bile flow Appetite stimulant Side Effects Sodium/water retention Catabolic Increased susceptibility infection GI ulceration Glucocorticoids

  30. Glucocorticoids • If ascites or oedema are a problem-use glucocorticoids that lack mineralocorticoid activity • Dexamethasone (try for every three day dosing to avoid excessive suppression P-A axis) • Taper dose to lowest effective level

  31. Azathioprine • Immunosuppression • More expensive than prednisolone • Steroid sparing • Side Effects • Bone marrow suppression • Hepatopathy • Pancreatitis • Toxic to humans

  32. Ursodeoxycholic Acid (UDCA) • Non Toxic hydrophilic bile acid • Choleretic • Decreases proportion toxic bile acids • Reduces the immune response • Increased production glutathione (GSH) and metallothionein in hepatocytes • Contraindicated EHBDO • 15mg/kg/day divided in 2 doses • Indicated in cholestatic disorders (not PSS or HL)

  33. Section 6 Anti-Oxidant Therapy

  34. Anti-Oxidants • Vitamin C (can be pro-oxidant) • S-Adenosyl-L-Methionine (SAMe) • Vitamin E • Silymarin • N-Acetlcysteine • Zinc* • UDCA*

  35. S-Adenosyl-L-Methione (SAMe) • Precursor of cysteine:one of AA that makes up glutathione (GSH) • GSH is a defense mechanism against oxidative stress. Depletion GSH:oxidative stress • Helps to restore depleted GSH in hepatocytes • 20mg/kg PO SID (empty stomach). • Do not split tabs • 2 isomers:ss and rs (the ss is the active form)

  36. Silymarin • Extracted from milk thistle • Free radical scavenger • Increases cellular SOD (main defense against oxidative damage) • Choleretic/anti-inflammatory • Indicated where main damage to liver is oxidative • Amanita mushroom intoxication • Paracetamol intoxication • 20-50mg/kg/day divided q6-8hr PO • No side effects

  37. Vitamin E • Dose:10-15 IU/kg /day PO • Indicated in liver dz associated with oxidative injury • Anti-inflammatory • Especially important in fat malabsorption (bile duct obstruction) • Copper toxicity • Paracetamol toxicity • No side Effects

  38. N-Acetylcysteine • Cytoprotective (along with SAMe, UDCA, Silymarin, Vit E) • Anti-oxidant (increases GSH) • Anti-Inflammatory • Improves hepatic circulation • Improves tissue O2 delivery • 140mg/kg IV once then 70mg/kg IV q6hr

  39. AntiFibrotic Drugs • Fibrosis end result of chronic inflammation • A lot of research into drugs to limit fibrosis/cirrhosis :all experimental at this stage • Colchicine: • Stimulates collagenase • Side Effects • HE, BM suppression, renal injury, neuropathy • 0.025-0.3mg/kg SID few days then EOD • NO evidence that it helps • Don’t use it (?if fibrosis is primary lesion)

  40. Anti Copper Medications • Free intracellular copper causes oxidative damage • Genetic disease • Bedlington Terriers • Skye Terriers • West Highland White Terriers • Dalmatians • Labradors • Dobermans • DNA test (don’t need a liver biopsy anymore) • Secondary to decreased bile excretion

  41. Anti-Copper Medications • Chelating Agents • Bind free extracellular copper ….excreted in urine….movement copper from intracellular space to extracellular space…decreases intracellular toxic pool • D Penacillamine (preferred) • Trientine (more potent) • 10-15mg/kg BID with food

  42. Anti-copper Medications(cont) • Zinc (gluconate or acetate) • Induces metallothionein in enterocytes-binds cu -sequestered in senescent enterocytes -sloughed..excreted • Give 1 hour Before meals • Don’t use chelators and zinc together • 10mg elemental zinc /kg BID • Watch for haemolytic anaemia (excess zinc) or iron deficiency

  43. Ascites • Rare in cats with liver dz • Portal hypertension w/o hypoalbuminaemia will only cause ascites RARELY (ie: A-V fistula, complete thrombosis portal vein) • Sodium restriction • Cage rest • Sodium wasting diuretics

  44. Ascites with Hepatobiliary Disease • Measure BW, abdominal girth, PCV, TS, BUN • Spironolactone 0.5-1.0mg/kg PO BID 3-4d • Frusemide 1.0mg/kg PO BID -4d • If respond :taper drugs to lowest effective dose

  45. Ascites With Hepatobiliary Disease • If no response:(and PCV/TS/BUN stable) • Spironolactone 2mg/kg PO BID 4d • If still no response (and PCV etc stable) • Frusemide 2mg/kg PO BID • Watch: • Hypokalemia • Dehydation

  46. Ascites (cont) :If still no response • Colloid Administration • Expand the ECF compartment:promote diuresis • Plasma preferred ($$$)

  47. Therapeutic Abdominocentesis • 18 or 16g catheter or open ended tom cat catheter through 14g teflon catheter • Remove over 1 hour • Can improve efficiency of diuretics • Risks: • Infection • Bleeding • Continued seroma formation at puncture site (lateral body wall) • Loss albumin • Hypotension (unlikely)

  48. Vitamin K • Deficiency possible with reduced hepatic function or cholestasis • Major Bile Duct Obstruction • 5-15mg (sm-lg dog) IM x3 doses q 12hours • OR • 0.5-1.5mg/kg IM 3 doses q 12 hrs • Then every 7-28d as needed (PIVKA test, PT, PTT) • Don’t give it IV (anaphylactic reactions)

  49. Vitamin K • CATS: • 5mg or 0.5-1.5mg/kg IM -3 doses q12 hours then 1-2x weekly PO until recovery • Watch for heinz body hemolytic anaemia • Monitor PCV/RBC morphology

More Related